An animal study shows that Xuesaitong (Panax notoginseng-based CPM) reduces brain infarct volume and alleviates neurological impairment 14 days after middle cerebral artery occlusion (MCAO), possibly by regulating microglial phenotypes via downregulation of the STAT3 signaling pathway16. The gene discussed is STAT3; the disease is brain infarction.